Medindia

X

Portola Pharmaceuticals Announces Late-Breaker Presentation on Betrixaban at American College of Cardiology's 59th Annual Scientific Session

Wednesday, February 10, 2010 General News J E 4
Advertisement

Oral Presentation Details

A Randomized Clinical Trial of Three Doses of a Long-Acting Oral Direct Factor Xa Inhibitor Betrixaban in Patients With Atrial Fibrillation (Presentation #3015-12)

Presenter: Dr. Michael D. Ezekowitz

Session: Late-Breaking Clinical Trials II: Cardiac Arrhythmias

Date: Monday, March 15, 8:51-9:03 a.m. ET

Location: Georgia World Congress Center, Murphy Ballroom

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Trimel Announces Significant Operational Execution
S
Physicians on Sermo Stunned by FTC Complaint Over ...